China Surpasses United States in R&D Spending Amid Uneven Global High-Tech Competition

China hits $1.03 trillion in R&D spending, surpassing the US in 2024. Explore how this high-tech drive is impacting global semiconductors and 5G standards.

By: AXL Media

Published: Apr 10, 2026, 11:04 AM EDT

Source: Information for this report was sourced from CSIS

The Surge in National Innovative Capacity and Investment

China’s trajectory within the global innovation landscape has undergone a radical shift over the past two decades, characterized by massive capital injections and strategic industrial planning. According to Scott Kennedy, a Senior Adviser at the Center for Strategic and International Studies, the nation now ranks tenth in the Global Innovation Index, a metric that serves as the international benchmark for innovative performance. This rise is underpinned by a historic milestone in 2024, where Chinese research and development spending, measured in purchasing power parity, reached $1.03 trillion. While the United States follows closely at $1.01 trillion, the composition of this funding differs sharply, as the Chinese model remains heavily reliant on direct government outlays compared to the corporate-led investment structure seen in the West.

Sectoral Success in Pharmaceuticals and Talent Integration

One of the most unexpected triumphs in the Chinese high-tech drive is the rapid expansion of its pharmaceutical sector. Despite a historical reputation for weak intellectual property protections, China now accounts for approximately 30 percent of new innovative drugs produced on a global scale. This success is primarily attributed to a massive influx of "returnee" talent—scientists and executives who were educated and employed by leading Western firms before returning home to launch local startups. These professionals have brought with them deep expertise in clinical trials and international regulatory standards, allowing the domestic industry to ramp up both novel drug discovery and generic manufacturing at an unprecedented pace.

Persistent Failures in the Commercial Aviation Market

In stark contrast to its medical and electronic successes, China’s attempt to challenge the global aerospace duopoly remains a notable failure. The Commercial Aircraft Corporation of China, or COMAC, delivered only 15 of its C919 narrow-body jetliners in 2025, a figure that fell drastically short of its 75-unit target. The program continues to struggle with production scaling and a heavy dependence on foreign technology, as nearly every critical system within the aircraft is sourced from suppliers in the United States, Europe, or Japan. The lack of transparency and poor coordination inherent in state-owned enterprises has hi...